Phase II Metabolite-Inspired Tripeptide Editing Generates Anti-Inflammatory Candidates for Treatment-Refractory Ulcerative Colitis
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188285 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xiaodi Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Research Group, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Anti-Inflammatory Agents, Oligopeptides. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Georgia State University Research Foundation, Advancing Research: Innovation and Scholarly Excellence (ARISE) Challenge Award.
Abstract (Originalsprache)
Ulcerative colitis remains a major clinical challenge due to limited availability of safe, orally active anti-inflammatory drugs. Although phase II metabolism is traditionally viewed as a detoxification process, certain metabolites retain or exhibit enhanced pharmacological activity, offering an underexplored drug discovery opportunity. Here, we investigated phase II metabolite-inspired tripeptide editing using M13, a glutathione-conjugated metabolite of the anti-inflammatory natural product 6-shogaol, as a lead scaffold. A focused library of 38 analogs was generated by systematic tripeptide editing while preserving the central cysteine-containing 6-shogaol-derived scaffold. Phenotypic nuclear factor-κB (NF-κB) reporter screening identified 29 of 38 analogs with greater inhibitory activity than M13 at the screening concentration. Two selected leads, MLY2 and MLY8, demonstrated enhanced anti-inflammatory activity in Dextran Sulfate Sodium-induced experimental colitis, including restoration of colon length and reductions in fecal lipocalin-2 and pro-inflammatory cytokines. Both compounds also suppressed inflammatory cytokine production more effectively than M13 in ex vivo colonic biopsies from patients with treatment-refractory ulcerative colitis. In parallel, MLY2 and MLY8 showed no detectable mutagenicity under the Ames assay conditions and were well tolerated in a preliminary single-dose maximum tolerated dose study. Collectively, these findings establish phase II metabolite-inspired tripeptide editing as a productive lead-discovery strategy and identify MLY2 and MLY8 as anti-inflammatory leads warranting further preclinical characterization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Disease Research Group, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
- School of Medicine, Wake Forest University, Winston-Salem, NC 27101, USA.
- Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30307, USA.
- Atlanta Veterans Affairs Medical Center, Decatur, GA 30302, USA.
ORCID-Profile: Xiaodi Shi, Rabeya Jafrin Mow, Dingpei Long, Chunhua Yang
Förderung
- Georgia State University Research Foundation
- Advancing Research: Innovation and Scholarly Excellence (ARISE) Challenge Award
Zitieren
APA
Shi, X., Mow, R. J., Long, D., Merlin-Zhang, O., Xu, E., Shi, X., Garg, P., Srinivasan, S., & Yang, C. (2026). Phase II Metabolite-Inspired Tripeptide Editing Generates Anti-Inflammatory Candidates for Treatment-Refractory Ulcerative Colitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188285
Vancouver
Shi X, Mow RJ, Long D, Merlin-Zhang O, Xu E, Shi X, et al. Phase II Metabolite-Inspired Tripeptide Editing Generates Anti-Inflammatory Candidates for Treatment-Refractory Ulcerative Colitis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188285
BibTeX
@article{Shi2026,
author = {Shi, Xiaodi and Mow, Rabeya Jafrin and Long, Dingpei and Merlin-Zhang, Olivier and Xu, Emma and Shi, Xiaomeng and Garg, Pallavi and Srinivasan, Shanthi and Yang, Chunhua},
title = {Phase II Metabolite-Inspired Tripeptide Editing Generates Anti-Inflammatory Candidates for Treatment-Refractory Ulcerative Colitis},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188285}
}
EUVIMED